BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
June 11, 2019
View Archived Issues
A case study exploring a novel AKT1 fusion-driven cancer
Read More
Cutting out the middleman for MSI-high diagnosis
Read More
Drivers or drifters?
Read More
Recruitment ongoing in phase II study of I-131-1095 plus enzalutamide in patients with mCRPC
Read More
FDA grants IND permission to PrimeVax for use of U.S. Army's dengue virus to treat cancer
Read More
FibroGen initiates phase III study of pamrevlumab plus chemotherapy in pancreatic cancer
Read More
Phase II results presented for PT-2385 in patients with glioblastoma
Read More
First-in-human data presented for the bispecific anti-PD-L1/CTLA-4 antibody KN-046
Read More
Safety and tolerability data from first-in-human trial of GX-G6 as potential antidiabetic
Read More
Arvinas patents new IRAK-4-targeting compounds
Read More
Innovate Biopharmaceuticals initiates first ever phase III study in celiac disease
Read More
Topline data presented from phase II study of NYX-2925 in patients with fibromyalgia
Read More
Harvard College and Eisai divulge new compounds for cancer
Read More
Hepagene Therapeutics identifies MAP3K5 inhibitors
Read More
Merck & Co. synthesizes new IDO1 inhibitors
Read More
Homology Medicines initiates phase I/II study for HMI-102 gene therapy for adults with PKU
Read More
Northwestern University presents GBA activators
Read More
FDA approves first chemoimmunotherapy regimen for patients with DLBCL
Read More
Positive topline results presented for phase II study of Gazyva in lupus nephritis
Read More
Primary objective of safety achieved in the midpoint of first-in-human study of PKX-001
Read More
AVA-004 selected as clinical candidate for development in Avacta's Affimer PD-L1 inhibitor platform
Read More
Cognitive deficits ameliorated in mouse Alzheimer's models
Read More
PPC-06 meets both coprimary endpoints in phase IIb study in plaque psoriasis
Read More
Tree SLIT-tablet against allergic rhinitis approved in Europe
Read More